Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03573661 · ClinicalTrials.gov registry record · NA

A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers

A NA study of Palpable Breast Cancer, sponsored by Dartmouth-Hitchcock Medical Center.

Completed
Registry status
NA
Development phase
18
Enrollment target
4
Study locations

NCT03573661 is a NA study of Palpable Breast Cancer that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 18 participants. The trial reports 4 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03573661, a NA study of Palpable Breast Cancer, has completed, sponsored by Dartmouth-Hitchcock Medical Center.

COMPLETED
Registry status
NA
Development phase
18 participants
Enrollment target
4
Study locations

Study Summary

The project objective is to determine whether the Breast Cancer Locator (BCL) can safely and effectively localize breast cancers in patients treated at locations distant from the site of BCL manufacture. This information will be transmitted to CairnSurgical, Inc. where the BCL will be fabricated, tested for quality assurance, sterilized and shipped to the patient's surgeon. The surgeon will then utilize the BCL at the time of resection of the palpable breast cancer.

Conditions Studied

Interventions

  • DEVICE Breast Cancer Locator (BCL)

Study Locations (4)

New Hampshire

  • Cheshire Medical Center - Keene
  • Dartmouth Hitchcock Medical Center - Lebanon
  • St. Joseph Hospital - Nashua

Massachusetts

  • Lahey Hospital & Medical Center (Lahey Clinic) - Burlington

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2018-05-24
Est. Completion 2021-04-05
Phase NA

Sponsor

Dartmouth-Hitchcock Medical Center

427 total trials

What the Registry Record Tells You About NCT03573661

The ClinicalTrials.gov registry entry for NCT03573661 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Palpable Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Breast Cancer Locator (BCL) is the first listed.

NCT03573661 reports 4 study locations spanning 2 distinct geographic areas - top geographies include New Hampshire, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03573661 about?

NCT03573661 is a clinical study titled "A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers". The project objective is to determine whether the Breast Cancer Locator (BCL) can safely and effectively localize breast cancers in patients treated at locations distant from the site of BCL manufacture. This information will be transmitted to CairnSurgical, Inc. where the BCL will be fabricated, te...

What is the current status of trial NCT03573661?

This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2018-05-24. Estimated completion is 2021-04-05.

What conditions does trial NCT03573661 study?

This clinical trial studies the following conditions: Palpable Breast Cancer.

What interventions are being tested in trial NCT03573661?

The interventions under investigation include: Breast Cancer Locator (BCL) (DEVICE).

Who is sponsoring clinical trial NCT03573661?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03573661 being conducted?

This trial has 4 study locations across Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.